Collegium Pharmaceutical Inc. (COLL) PT Set at $23.00 by Piper Jaffray Cos.
Collegium Pharmaceutical Inc. (NASDAQ:COLL) has been given a $23.00 price target by equities research analysts at Piper Jaffray Cos. in a research report issued on Wednesday. The firm presently has a a “buy” rating on the specialty pharmaceutical company’s stock. Piper Jaffray Cos.’s target price would indicate a potential upside of 26.44% from the stock’s current price.
Other research analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday. Gabelli began coverage on shares of Collegium Pharmaceutical in a research report on Tuesday, September 13th. They set a “buy” rating and a $25.00 target price on the stock. Jefferies Group restated a “buy” rating on shares of Collegium Pharmaceutical in a research report on Thursday, September 22nd. Finally, Needham & Company LLC restated a “buy” rating and set a $30.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, September 14th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Collegium Pharmaceutical has a consensus rating of “Buy” and a consensus target price of $27.60.
Collegium Pharmaceutical (NASDAQ:COLL) traded up 0.687% on Wednesday, reaching $18.315. 220,228 shares of the company traded hands. The stock has a 50-day moving average of $13.30 and a 200 day moving average of $14.54. The company’s market capitalization is $430.92 million. Collegium Pharmaceutical has a 52-week low of $8.24 and a 52-week high of $30.58.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/collegium-pharmaceutical-inc-coll-pt-set-at-23-00-by-piper-jaffray-cos.html
Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.29. On average, equities analysts forecast that Collegium Pharmaceutical will post ($3.86) EPS for the current year.
In other news, Director John A. Fallon purchased 2,375 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, August 12th. The shares were acquired at an average price of $10.59 per share, for a total transaction of $25,151.25. Following the transaction, the director now owns 2,375 shares of the company’s stock, valued at approximately $25,151.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 37.93% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Nationwide Fund Advisors raised its stake in Collegium Pharmaceutical by 73.3% in the second quarter. Nationwide Fund Advisors now owns 8,665 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 3,665 shares in the last quarter. Alliancebernstein L.P. bought a new position in shares of Collegium Pharmaceutical during the second quarter valued at approximately $122,000. Royal Bank of Canada increased its position in shares of Collegium Pharmaceutical by 2.7% in the second quarter. Royal Bank of Canada now owns 11,600 shares of the specialty pharmaceutical company’s stock valued at $137,000 after buying an additional 300 shares during the last quarter. Rhumbline Advisers bought a new position in shares of Collegium Pharmaceutical during the second quarter valued at approximately $143,000. Finally, A.R.T. Advisors LLC bought a new position in shares of Collegium Pharmaceutical during the second quarter valued at approximately $148,000. Institutional investors and hedge funds own 62.13% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.